The short version of obesity research fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-30. Anything still debated is marked as such rather than presented as settled.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
== Occurrence == Dimethyl trisulfide has been found in volatiles emitted from cooked onion, leek and other Allium species, from broccoli and cabbage, as well as from Limburger cheese, and is involved in the unpalatable aroma of aged beer and stale Japanese sake. It is a product of bacterial decomposition, including the early stages of human decomposition, and is a major attractant for blowflies looking for hosts. Dimethyl trisulfide along with dimethyl sulfide and dimethyl disulfide have been confirmed as volatile compounds given off by the fly-attracting plant known as dead-horse arum (Helicodiceros muscivorus). These flies are attracted to the odor of fetid meat and help pollinate this plant. DMTS contributes to the foul odor given off by the fungus Phallus impudicus, also known as the common stinkhorn. DMTS causes the characteristic malodorous smell of a fungating lesion, e.g., from cancer wounds, and contributes to the odor of human feces. DMTS can be synthesized by the reaction of methanethiol with hydrogen sulfide (in the presence of copper (II)) and with sulfur dichloride, among other methods:
== Bibliography == Ralston SH, Penman ID, Strachan MW, Hobson RP (2018). Davidson's principles and practice of medicine (23rd ed.). Elsevier. ISBN 978-0-7020-7028-0. Hoffbrand V, Moss PA (2016). Hoffbrand's essential haematology (7th ed.). West Sussex: Wiley Blackwell. ISBN 978-1-1184-0867-4.
== History == In 1943, diphenhydramine was discovered by chemist George Rieveschl and one of his students, Fred Huber, while they were conducting research into muscle relaxants at the University of Cincinnati. Huber first synthesized diphenhydramine. Rieveschl then worked with Parke-Davis to test the compound, and the company licensed the patent from him. In 1946, it became the first prescription antihistamine in the United States approved by the FDA. In the 1960s, diphenhydramine was found to weakly inhibit reuptake of the neurotransmitter serotonin. This discovery led to a search for viable antidepressants with similar structures and fewer side effects, culminating in the invention of fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). A similar search had previously led to the synthesis of the first SSRI, zimelidine, from brompheniramine, also an antihistamine. In 1975, diphenhydramine was still available only by prescription in the US and required medical supervision.
10 October On the advice of Kissinger, Nixon issued secret orders to the Joint Chiefs of Staff to commence Operation Giant Lance, the sending of bombers armed with nuclear weapons toward Moscow in an effort to convince the Soviet leaders that he was not reluctant to launch a nuclear war in an effort to end the ongoing war. A squadron of 18 B-52 bombers, each carrying nuclear bombs, would be sent out on 27 October.
Sources: en.wikipedia.org
== Contents == A 1958 source describes Dover's Powder as follows: "Powder of Ipecacuanha and Opium (B.P., Egyp. P., Ind. P.). Pulv. Ipecac. et Opii; Ipecac and Opium Powder (U.S.N.F.); Dover's Powder; Compound Ipecacuanha Powder. Prepared ipecacuanha, 10 g., powdered opium 10 g., lactose 80 g. It contains 1% of anhydrous morphine. Dose: 320 to 640 mg. (5 to 10 grains). Many foreign pharmacies include a similar powder, sometimes with potassium sulphate or with equal parts of potassium nitrate and potassium sulphate in place of lactose; max. single dose 1 to 1.5 g. and max. in 24 hours 4 to 6 g."
== History == In the 1930s, hydrocortisone was found by biochemist Edward C. Kendall and rheumatologist Philip S. Hench, who were both Nobel laureates. When they were investigating therapies for rheumatoid arthritis, they discovered that female patients of the disease would experience an alleviation of their condition if they were pregnant at the same time. It was also found that patients suffering from both rheumatoid arthritis and jaundice would have fewer symptoms associated with rheumatoid arthritis. Following this finding, they extracted different hormones from the adrenal cortex of cows in search of a suitable drug. They first identified cortisone to be one of the possible drugs, and further research led them to discover an effective drug for human dermal problems, which was hydrocortisone. After the discovery of hydrocortisone, the earliest application of hydrocortisone as a topical form in humans was recorded in 1952. Its successful utilization facilitated more research on topical corticosteroids, which helped the development of similar drugs with higher activity.
Absolute waist circumference (>102 cm (40 in) in men and >88 cm (35 in) in women) Waist–hip ratio (the circumference of the waist divided by that of the hips of >0.9 for men and >0.85 for women) Waist-stature ratio (waist circumference divided by their height, >0.5 for adults under 40 and >0.6 for adults over 50) Sagittal Abdominal Diameter
== Stationary Phase == One of the key factors influencing HILIC separations is the chemical nature of the stationary phase that is packed into the column. Stationary phases on HILIC columns not only provide physical support for the water layer which analytes separate into, but also interact with the analytes through hydrogen bonding and electrostatic interactions, affecting their retention and therefore the mechanism of separation. Typical HILIC stationary phases are polar, made of classical bare silica or silica gels modified with various polar groups. Some commonly used stationary phases include bare silica, or silica chemically bonded to amino-, amide-, cyano-, or diol- groups. Ion exchanger groups, both cationic and anionic , as well as zwitterionic groups are also commonly used. While most HILIC phases are polar, there have also been exceptions where non-polar bonded silicas are used with extremely high organic solvent composition. In this case, interactions are affected by exposed patches of silica in between the bonded ligands on the support.
=== Mechanism === Legumain is a cysteine protease from the C13 family of the CD clan of proteases (MEROPS). It uses a catalytic triad of Cysteine-Histidine-Asparagine in its active site to perform covalent proteolysis of its substrate.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.